Takeda (TSE:4502/NYSE:TAK), a global values-based R&D-driven biopharmaceutical leader headquartered in Japan, translates science into innovative medicines. It focuses its R&D efforts on four therapeutic areas: oncology, rare diseases, neuroscience and gastroenterology. It also makes R&D investments in plasma-derived therapies and vaccines. Takeda is focusing on developing innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging enhanced collaborative R&D engines and capabilities to create a modality-diverse pipeline. Its employees are committed to improving quality of life for patients and to working with healthcare partners in some 80 countries.